Hodgkin LymphomaPhase 3FIL_PRIORITYNCT07256158
PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma
A Phase 3 study testing 20 Gy Involved site radiotherapy and 30 Gy Involved site radiotherapy in people with Hodgkin Lymphoma, run by Fondazione Italiana Linfomi - ETS at 38 sites in Italy.
Trial summary
The final analysis of GHSG HD11 study (not PET driven) showed that 30 Gy IFRT still remains the standard dose after 4 ABVD. Early PET negativity might allow safe radiation de-escalation in patients achieving a metabolic complete response after 2 ABVD. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hodgkin Lymphoma
- What is being tested?
- 20 Gy Involved site radiotherapy and 30 Gy Involved site radiotherapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 518 participants
- Where
- 38 sitesItaly
- Study dates
- 10 Jul 2026to Aug 2033
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years;
- Histologically confirmed classical HL stage I, II unfavorable according to GHSG criteria;
- Patient with any nodal mass ≥ than 10 cm can be included
- No previous treatment for Hodgkin lymphoma;
- ECOG performance status 0 to 2;
- Presence of FDG-avid lymphoma lesions on baseline PET scan;
Show all 16Show fewer
- Subject understands and voluntarily signs the informed consent form approved by the Independent Ethics Committee (IEC), prior to the initiation of any screening or study-specific procedures;
- Adequate organ and marrow function as defined below:
- absolute neutrophil count > 1.0 x109/L
- platelet count > 75 x109/L
- Total bilirubin < 2 mg/dl without a pattern consistent with Gilbert's syndrome
- Aspartate Transaminase and Alanine Transaminase (AST/ALT) < 3.0 X institutional Upper Limits of Normality (ULN)
- Creatinine within normal institutional limits or creatinine clearance > 50 mL/min
- Women of childbearing potential must agree to use a highly effective method of contraception (oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device) from the signature of informed consent until six months after the last dose of treatment;
- Men must agree to use a highly effective method of contraception (barrier contraception or abstinence, when this is in line with the usual lifestyle of the subject) from the signature of informed consent until six months after the last dose of treatment;
- Women of childbearing potential must have a negative serum pregnancy test at screening.
Who cannot join
- Patients who meet any of the following criteria are not eligible to enroll:
- Stage II B- III- IV
- Hodgkin Lymphoma as "composite lymphoma" or nodular lymphocyte prevalence histological subtype
- Active HBV and HCV infection
- HIV seropositivity
- Pre-treatment with chemotherapy or radiation therapy
Show all 10Show fewer
- Malignant disease within the last 5 years (excluding basal skin tumors and carcinoma in situ of the cervix)
- Women who are pregnant or breast feeding
- Absence of FDG-avid lymphoma lesions on baseline PET scan
- Significant history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent.
Trial locations and contacts
38 sites in 1 country. Contact the study team or a site near you to ask about taking part.
38 sites in 1 country
Italy38 sites, 38 recruiting
- Not yet recruiting
A.O.U. SS. Antonio e Biagio e C. Arrigo - S.C.D.U. Ematologia
Alessandria
Manuela Zanni, MD, manuela.zanni@ospedale.al.it
Manuela Zanni, MD
- Not yet recruiting
A.O.R.N. G Moscati - U.O.C. Ematologia e Terapie cellulari avanzate
Avellino
Sonya De Lorenzo, MD, sonya.delorenzo@aornmoscati.it
Sonya De Lorenzo, MD
- Not yet recruiting
IRCCS Centro Riferimento Oncologico - S.O.C. Oncologia medica e dei tumori immuno-correlati
Aviano
Michele Spina, MD, mspina@cro.it
Michele Spina, MD
- Not yet recruiting
ASST Papa Giovanni XXIII - S.C. Ematologia
Bergamo
Silvia Ferrari, MD, s.ferrari@asst-pg23.it
Silvia Ferrari, MD
- Not yet recruiting
Clinica Humanitas Gavazzeni - U.O. Oncologia Medica
Bergamo
Daniele Laszlo, MD, daniele.laszlo@gavazzeni.it
Daniele Laszlo, MD
- Not yet recruiting
ASST Spedali Civili - S.C. Ematologia
Brescia
Chiara Pagani, MD, chiara.pagani@asst-spedalicivili.it
Chiara Pagani, MD
- Not yet recruiting
ARNAS "Brotzu" P.O. Businco - S.C. Ematologia e TMO
Cagliari
Valeria Oggianu, MD, valeria.oggianu@aob.it
Valeria Oggianu, MD
- Not yet recruiting
I.R.C.C.S. Istituto di Candiolo - FPO
Candiolo
Umberto Vitolo, MD, umberto.vitolo@ircc.it
Umberto Vitolo, MD
- Not yet recruiting
ARNAS Garibaldi - U.O.C. Ematologia
Catania
Ugo Consoli, MD, uconsoli@arnasgaribaldi.it
Ugo Consoli, MD
- Not yet recruiting
A.O. S. Croce e Carle - S.C. Ematologia
Cuneo
Roberto Sorasio, MD, sorasio.r@ospedale.cuneo.it
Roberto Sorasio, MD
- Not yet recruiting
A.S.L. Toscana Centro - SOC Oncoematologia
Florence
Sabrina Moretti, MD, sabrina.moretti@uslcentro.toscana.it
Sabrina Moretti, MD
- Not yet recruiting
Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia
Florence
Benedetta Puccini, MD, puccinib@aou-careggi.toscana.it
Benedetta Puccini, MD
- Not yet recruiting
IRCCS Policlinico S. Martino - U.O. Ematologia e terapie cellulari
Genova
Chiara Ghiggi, MD, chiara.ghiggi@hsanmartino.it
Chiara Ghiggi, MD
- Not yet recruiting
ASL Latina Ospedale S. Maria Goretti - UOC Ematologia con trapianto
Latina
Natalia Cenfra, MD, nataliacenfra81@gmail.com
Natalia Cenfra, MD
- Not yet recruiting
ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia
Milan
Vittorio Riggero Zilioli, MD, vittorioruggero.zilioli@ospedaleniguarda.it
Vittorio Ruggero Zilioli, MD
- Not yet recruiting
IRCCS Fondazione Istituto Nazionale Tumori - S.C. Ematologia
Milan
Paolo Corradini, MD, paolo.corradini@unimi.it
Paolo Corradini, MD
- Not yet recruiting
A.O.U. Ospedale Maggiore della Carità - S.C.D.U. Ematologia
Novara
Riccardo Bruna, MD, riccardo.bruna@maggioreosp.novara.it
Riccardo Bruna, MD
- Not yet recruiting
A.O.U. di Padova - U.O.C. Ematologia
Padova
Andrea Visentin, MD, andrea.visentin@aopd.veneto.it
Andrea Visentin, MD
- Not yet recruiting
I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncologia 1
Padova
Dario Marino, MD, dario.marino@iov.veneto.it
Dario Marino, MD
- Not yet recruiting
A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia
Palermo
Caterina Patti, MD, k.patti@villasofia.it
Caterina Patti, MD
- Not yet recruiting
IRCCS Fondazione Policlinico S. Matteo - S.C. Ematologia 1
Pavia
Manuel Gotti, MD, ma.gotti@smatteo.pv.it
Manuel Gotti, MD
- Not yet recruiting
A.O. Ospedale S. Maria della Misericordia - Ematologia
Perugia
Leonardo Flenghi, MD, leonardo.flenghi@ospedale.perugia.it
Leonardo Flenghi, MD
- Not yet recruiting
AUSL di Piacenza Ospedale Guglielmo da Saliceto - U.O.C. Ematologia e centro trapianti
Piacenza
Annalisa Arcari, MD, a.arcari@ausl.pc.it
Annalisa Arcari, MD
- Not yet recruiting
AUSL di Ravenna Osp. S. Maria delle Croci - U.O.C. Ematologia
Ravenna
Monica Tani, MD, monica.tani@auslromagna.it
Monica Tani, MD
- Not yet recruiting
AUSL IRCCS Arcispedale S. Maria Nuova - S.C. Ematologia
Reggio Emilia
Angela Ferrari, MD, ferrari.angela@ausl.re.it
Angela Ferrari, MD
- Not yet recruiting
A.O.U. Policlinico Umberto I - U.O.C Ematologia
Roma
Ilaria Del Giudice, MD, ilaria.delgiudice@uniroma1.it
Ilaria Del Giudice, MD
- Not yet recruiting
A.O.U. Sant'Andrea - U.O.C. Ematologia
Roma
Giacinto La Verde, MD, glaverde@ospedalesantandrea.it
Giacinto La Verde, MD
- Not yet recruiting
Fondazione Policlinico Campus Bio-Medico - U.O.C. Ematologia e trapianto di cellule staminali
Roma
Luigi Rigacci, MD, l.rigacci@policlinicocampus.it
Luigi Rigacci, MD
- Not yet recruiting
IRCCS Humanitas - U.O. Ematologia
Rozzano
Francesca Ricci, MD, francesca.ricci@humanitas.it
Francesca Ricci, MD
- Not yet recruiting
IRCCS Fondazione Casa Sollievo della Sofferenza - UOC Ematologia e Trapianto di Cellule Staminali Ematopoietiche
San Giovanni Rotondo
Angelo Michele Carella, MD, am.carella@operapadrepio.it
Angelo Michele Carella, MD
- Not yet recruiting
A.O.U. Senese - U.O.C. Ematologia
Siena
Alberto Fabbri, MD, fabbri7@unisi.it
Alberto Fabbri, MD
- Not yet recruiting
A.O. Santa Maria - S.C. Oncoematologia
Terni
Arcangelo Liso, MD, arcangelo.liso@unipg.it
Arcangelo Liso, MD
- Not yet recruiting
A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U
Torino
Candida Vitale, MD, candida.vitale@unito.it
Candida Vitale, MD
- Recruiting
A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia
Torino
Barbara Botto, MD, bbotto@cittadellasalute.to.it
Barbara Botto, MD
- Not yet recruiting
ULSS 2 Ospedale Ca' Foncello - U.O.C. Ematologia
Treviso
Piero Maria Stefani, MD, pieromaria.stefani@aulss2.veneto.it
Piero Maria Stefani, MD
- Not yet recruiting
A.S.U. Giuliano Isontina - S.C. Ematologia
Trieste
Francesco Zaja, MD, francesco.zaja@asugi.sanita.fvg.it
Francesco Zaja, MD
- Not yet recruiting
A.S.U. Friuli Centrale - Clinica Ematologica
Udine
Jacopo Olivieri, MD, jacopo.olivieri@asufc.sanita.fvg.it
Jacopo Olivieri, MD
- Not yet recruiting
A.O.U.I. di Verona - U.O.C. Ematologia
Verona
Andrea Bernardelli, MD, andrea.bernardelli@aovr.veneto.it
Andrea Bernardelli, MD
About this study
Official title: PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma: a Randomized, Phase III, Non-inferiority studY (PRIORITY Study)
The final analysis of GHSG HD11 study (not PET driven) showed that 30 Gy IFRT still remains the standard dose after 4 ABVD.
Early PET negativity might allow safe radiation de-escalation in patients achieving a metabolic complete response after 2 ABVD.
The aim of Priority trial is to explore whether radiotherapy could be safely deescalated to 20 Gy without loss of efficacy in patients treated with four cycles of ABVD who achieved complete metabolic response after the first two cycles.
- Conditions
- Hodgkin Lymphoma
- Being tested
- 20 Gy Involved site radiotherapy, 30 Gy Involved site radiotherapy
- Keywords
- Hodgkin lymphoma, Early stage, unfavourable, untreated, ABVD, chemotherapy, radiotherapy, 20 Gy, 30 Gy, randomization, PET guided, involved site
- Medical subject headings
- Hodgkin Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
20 Gy Involved site radiotherapyRadiation
Total dose 20 Gy Involved site radiotherapy
30 Gy Involved site radiotherapyRadiation
Total dose 30 Gy Involved site radiotherapy
| Study group | Role | What they receive |
|---|---|---|
| Experimental arm - 20 Gy Radiotherapy | Experimental | Involved site radiotherapy (ISRT) Total dose of 20 Gy is administered in 10 daily fractions of 2.0 Gy, five times a week over 2 weeks Receives: Radiation: 20 Gy Involved site radiotherapy |
| Comparator arm - 30 Gy Radiotherapy | Active comparator | Involved site radiotherapy (ISRT) Total dose of 30 Gy is administered in 15 daily fractions of 2.0 Gy, five times a week over 3 weeks Receives: Radiation: 30 Gy Involved site radiotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate if de-escalated ISRT dose (20 Gy) is not inferior to conventional ISRT dose (30 Gy) in terms of PFS in patients with newly diagnosed early-stage unfavourable HL achieving a complete metabolic response (DS 1-3) after 2 ABVD cycle
Progression-Free Survival (PFS) of the randomized population. Subjects with incomplete follow-up or with no disease evaluation will be censored at the date of last available documented status of freedom from failure.
Measured: From the date of randomization to documented relapse, progression or to the patient's death as a result of any causes (up to 82 months).
Secondary outcomes (5)
To compare OS rates between de-escalated ISRT dose (20 Gy) and conventional ISRT dose (30 Gy) in patients with newly diagnosed early-stage unfavourable HL achieving a complete metabolic response (DS 1-3) after 2 ABVD cycles;
Overall Survival (OS) for the randomized population
Measured: From the time of randomization to death from any cause (up to 82 months)
To evaluate PFS for the whole population
Progression free survival for the whole enrolled population
Measured: From the date of consent to documented relapse, progression or death from any cause (up to 84 months)
To evaluate OS for the whole population
Overall Survival (OS) for the whole population
Measured: From the date of consent to death from any cause (up to 84 months)
To describe pattern of failure "in field", "marginal field", "out of field" relapse after conventional and reduced ISRT;
Incidence and severity of Adverse Events, graded according to the latest version of the Common Terminology Criteria for Adverse Events (CTCAE v 5.0) during the treatment
Measured: From the date of consent to death from any cause (up to 84 months)
To report details on RT treatment volumes and dose distributions and to estimate the dose received by the organs at risk (OARs) in the two treatment arms
RT dose received by organs at risk (OARs).
Measured: At time of radiotherapy (about 4 months from chemotherapy start)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2025
- Study start10 Jul 2026
- Primary completionDec 2029 (estimated)
- Study completionAug 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hodgkin LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized, Phase III, Non-inferiority study
- Masking
- None (open label)
- Enrolment
- 518 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fondazione Italiana Linfomi - ETS
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Umberto Ricardi, MD, Principal investigator, SC Radioterapia U - AOU Città della Salute e della Scienza di Torino
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07256158
- Sponsor's protocol ID
- FIL_PRIORITY
- Acronym
- FIL_PRIORITY
- Status last verified
- Aug 2026
- First submitted
- 20 Nov 2025
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma: a Randomized, Phase III, Non-inferiority studY (PRIORITY Study)
- ClinicalTrials.gov ID
- NCT07256158
- Acronym / sponsor ID
- FIL_PRIORITY / FIL_PRIORITY
- Conditions
- Hodgkin Lymphoma
- Keywords
- Hodgkin lymphoma, Early stage, unfavourable, untreated, ABVD, chemotherapy, radiotherapy, 20 Gy
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 518 participants (estimated)
- Lead sponsor
- Fondazione Italiana Linfomi - ETSUniversity, hospital or other
- Study start
- 10 Jul 2026 (actual)
- Primary completion
- Dec 2029 (estimated)
- Study completion
- Aug 2033 (estimated)
- First posted
- 1 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The final analysis of GHSG HD11 study (not PET driven) showed that 30 Gy IFRT still remains the standard dose after 4 ABVD.
Early PET negativity might allow safe radiation de-escalation in patients achieving a metabolic complete response after 2 ABVD.
The aim of Priority trial is to explore whether radiotherapy could be safely deescalated to 20 Gy without loss of efficacy in patients treated with four cycles of ABVD who achieved complete metabolic response after the first two cycles.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomized, Phase III, Non-inferiority study
| Arm | Type | Receives |
|---|---|---|
| Experimental arm - 20 Gy Radiotherapy | Experimental | Radiation: 20 Gy Involved site radiotherapyInvolved site radiotherapy (ISRT) Total dose of 20 Gy is administered in 10 daily fractions of 2.0 Gy, five times a week over 2 weeks |
| Comparator arm - 30 Gy Radiotherapy | Active comparator | Radiation: 30 Gy Involved site radiotherapyInvolved site radiotherapy (ISRT) Total dose of 30 Gy is administered in 15 daily fractions of 2.0 Gy, five times a week over 3 weeks |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Age ≥18 years;
- Histologically confirmed classical HL stage I, II unfavorable according to GHSG criteria;
- Patient with any nodal mass ≥ than 10 cm can be included
- No previous treatment for Hodgkin lymphoma;
- ECOG performance status 0 to 2;
Key exclusion criteria (10 listed)
- Patients who meet any of the following criteria are not eligible to enroll:
- Stage II B- III- IV
- Hodgkin Lymphoma as "composite lymphoma" or nodular lymphocyte prevalence histological subtype
- Active HBV and HCV infection
- HIV seropositivity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 20 Gy Involved site radiotherapyTotal dose 20 Gy Involved site radiotherapy | Radiation | Experimental arm - 20 Gy Radiotherapy |
| 30 Gy Involved site radiotherapyTotal dose 30 Gy Involved site radiotherapy | Radiation | Comparator arm - 30 Gy Radiotherapy |
Primary outcome
To evaluate if de-escalated ISRT dose (20 Gy) is not inferior to conventional ISRT dose (30 Gy) in terms of PFS in patients with newly diagnosed early-stage unfavourable HL achieving a complete metabolic response (DS 1-3) after 2 ABVD cycle
Time frame: From the date of randomization to documented relapse, progression or to the patient's death as a result of any causes (up to 82 months).
Progression-Free Survival (PFS) of the randomized population. Subjects with incomplete follow-up or with no disease evaluation will be censored at the date of last available documented status of freedom from failure.
5 secondary outcomes
To compare OS rates between de-escalated ISRT dose (20 Gy) and conventional ISRT dose (30 Gy) in patients with newly diagnosed early-stage unfavourable HL achieving a complete metabolic response (DS 1-3) after 2 ABVD cycles;
Time frame: From the time of randomization to death from any cause (up to 82 months)
To evaluate PFS for the whole population
Time frame: From the date of consent to documented relapse, progression or death from any cause (up to 84 months)
To evaluate OS for the whole population
Time frame: From the date of consent to death from any cause (up to 84 months)
To describe pattern of failure "in field", "marginal field", "out of field" relapse after conventional and reduced ISRT;
Time frame: From the date of consent to death from any cause (up to 84 months)
To report details on RT treatment volumes and dose distributions and to estimate the dose received by the organs at risk (OARs) in the two treatment arms
Time frame: At time of radiotherapy (about 4 months from chemotherapy start)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Hodgkin Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
Active, not recruitingObservational study
Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma
Extranodal NK/T-cell Lymphoma, Nasal Type
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Umberto Ricardi, MD principal investigator
SC Radioterapia U - AOU Città della Salute e della Scienza di Torino
38 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing 20 Gy Involved site radiotherapy and 30 Gy Involved site radiotherapy in people with Hodgkin Lymphoma, run by Fondazione Italiana Linfomi - ETS at 38 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 38 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Uffici Studi FIL (+390131033153, startup@filinf.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate if de-escalated ISRT dose (20 Gy) is not inferior to conventional ISRT dose (30 Gy) in terms of PFS in patients with newly diagnosed early-stage unfavourable HL achieving a complete metabolic response (DS 1-3) after 2 ABVD cycle (time frame: From the date of randomization to documented relapse, progression or to the patient's death as a result of any causes (up to 82 months).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.